# A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

> **NCT00529581** · PHASE2 · COMPLETED · sponsor: **Cognition Pharmaceuticals, LLC** · enrollment: 150 (estimated)

## Conditions studied

- Cognition Disorders
- Multiple Sclerosis

## Interventions

- **DRUG:** C105

## Key facts

- **NCT ID:** NCT00529581
- **Lead sponsor:** Cognition Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-03
- **Final completion:** 2008-04
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2008-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00529581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00529581, "A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00529581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*